Home 2019-12-10T00:49:29+00:00

Open Science for Children’s Health

M4K Pharma is using open science to revolutionize how affordable new treatments are discovered and developed. Through our Medicines4Kids program, we are aggregating and aligning the work of global academics, foundations and pharma/biotech researchers to advance new cures for childhood diseases not well served by current business models.

M4K Pharma’s first program is the discovery, development and commercialization of an ALK2 enzyme inhibitor which will provide the first therapeutic developed specifically for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG).

M4K Pharma’s Data:
In line with M4K Pharma’s open science principles, we are committed to sharing our research data freely in the public domain. Our data is currently available for public viewing in the video recordings of our monthly open scientific updates, which are posted to our Blog and also available through our YouTube Channel. Data will be openly available in a downloadable format soon.

@aledmedwards and others have been making the case and leading by example (e.g. @thesgconline & @M4KPharma) to show that 🇨🇦 needs an ecosystem approach to drug & vaccine discovery/development, guided by principles of open science, patient access, and affordability - not profits.

@samoore_ Gonna tag @M4KPharma & @m4ndpharma in case you haven't heard of them and need a new open science compatible model to chew over. The more we can get the word out about new ways of doing drug development the better.

Data exclusivity provides the strongest protection of a drug’s marketing rights. Much stronger than a patent. Yet few pharma execs and few IP policy people even know about it! It’s the key to the @M4KPharma business model and our ability to price drugs affordably.

as a mum and as a professional in health care, I am so admirative of @aledmedwards and his team on their @M4KPharma project! we need more #openscience #ourpatientsdeserveit https://t.co/VytZeu3FtG

Affordable access to effective new medicines should be a human right. That’s what a large group of #openscience folks are working toward in @M4KPharma.
(paper open access soon)
@thesgconline @ReactionBiology @BrainTumourOrg
@CRiverLabs @OICR_news

Load More...

Latest Blog Posts